About ADMET & Toxicity Prediction
The ADMET & Toxicity Prediction category is part of the AI Drug Discovery market map, tracking 11 companies building in this segment. Target discovery, molecular design, protein folding, and clinical trial optimization accelerating the path from lab to patient. Curated by Hartmann Capital's venture research team.
Companies in ADMET & Toxicity Prediction
- Simulations Plus — Public
- Certara — Public
- Schrödinger — Public, $162M
- Cyclica — Acquired, $23M
- Collaborations Pharma — Seed, $5M
- molab.ai — Seed
- CarbonSilicon AI — Series A, $10M
- Cortex Discovery — Seed
- XtalPi — Series D, $785M
- Optibrium — Growth, $15M
- Lhasa Limited — Non-Profit
Frequently Asked Questions
- What companies are in the ADMET & Toxicity Prediction category?
- The ADMET & Toxicity Prediction category includes 11 companies: Simulations Plus, Certara, Schrödinger, Cyclica, Collaborations Pharma, molab.ai, CarbonSilicon AI, Cortex Discovery, XtalPi, Optibrium, Lhasa Limited. This is part of the AI Drug Discovery market map maintained by Hartmann Capital.
- How many ADMET & Toxicity Prediction startups are tracked?
- Hartmann Capital tracks 11 companies in the ADMET & Toxicity Prediction segment of the AI Drug Discovery market map.
- What are the best funded ADMET & Toxicity Prediction companies?
- Top funded companies in ADMET & Toxicity Prediction include XtalPi ($785M), Schrödinger ($162M), Cyclica ($23M), Optibrium ($15M), CarbonSilicon AI ($10M). Browse the full list in the AI Drug Discovery market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.